Park Avenue Institutional Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Park Avenue Institutional Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-493	Closed	-$172K	–	334
2016 Q2	$172K	Buy	493 +3	+0.6%	+$1.16K	0.15%	161
2016 Q1	$177K	Sell	490 -15	-3%	-$6.18K	0.15%	156
2015 Q4	$274K	Sell	505 -9	-2%	-$4.88K	0.24%	102
2015 Q3	$239K	Buy	514 +16	+3%	+$8.59K	0.21%	116
2015 Q2	$254K	Buy	+498	New	+$243K	0.2%	125

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Park Avenue Institutional Advisers's REGN Position: Q3 2016 in Review

Park Avenue Institutional Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 493 shares — an estimated $172K sold.

Park Avenue Institutional Advisers first reported a position in REGN in Q2 2015 and held it in 5 quarters. The position peaked at $274K in Q4 2015. 555 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

Park Avenue Institutional Advisers reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Park Avenue Institutional Advisers sold 493 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $172K.
Park Avenue Institutional Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Park Avenue Institutional Advisers's Regeneron Pharmaceuticals position peaked at $274K in Q4 2015.
555 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Park Avenue Institutional Advisers's 13F filing for Q3 2016, filed 15 Feb 2017.